A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier

Movement Disorders

Volumn 31, Issue 3, 2016, Pages 405-409

  Wile, Daryl J ^a   Dinelle, Katie ^a   Vafai, Nasim ^a   Mckenzie, Jessamyn ^a   Tsui, Joseph K ^a   Schaffer, Paul ^b   Ding, Yu Shin ^c   Farrer, Matthew ^a   Sossi, Vesna ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TRIUMF   (Canada)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

LRRK2; Parkinson's disease; SWEDD

Indexed keywords

6 FLUORODOPA F 18; CARBIDOPA; DIHYDROTETRABENAZINE C 11; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; N,N DIMETHYL 2 (2 AMINO 4 CYANOPHENYLTHIO)BENZYLAMINE C 11; ROPINIROLE; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; DOPAMINE; LEUCINE; LRRK2 PROTEIN, HUMAN;

ADULT; ARTICLE; BRAIN REGION; CASE REPORT; DENERVATION; DISEASE DURATION; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MIDDLE AGED; MUTATIONAL ANALYSIS; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; TOMOGRAPHY SYSTEM; BRAIN; GENETICS; HETEROZYGOTE; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; SCINTISCANNING;

BRAIN; DOPAMINE; FEMALE; HETEROZYGOTE; HUMANS; LEUCINE; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MIDDLE AGED; MUTATION; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING;

EID: 84952333587     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26450     Document Type: Article

References (23)

1. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003;54:93-101.
2. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
3. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
4. The Parkinson Study Group PRECEPT investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490.
5. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
6. Hornykiewicz O. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 1975;(3):13-21.
7. Marek K, Seibyl J, Sberly S, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014;82:1791-1797.
8. Batla A, Erro R, Stamelou M, et al. Patients with scans without evidence of dopaminergic deficit: a long term follow up study. Mov Disord 2014;29:1820-1825.
9. Menéndez-González M, Tavares F, Zeidan N, Salas-Pacheco JM, Arias-Carrión O. Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study. Front Aging Neurosci 2014;6:56.
10. Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic Value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008;59:258-266.
11. Sprenger FS, Seppi K, Djamshidian A, et al. Nonmotor symptoms in subjects without evidence of dopaminergic deficits. Mov Disord 2015;30:976-981.
12. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583.
13. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008;71:1790-1795.
14. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
15. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011;134:3290-3298.
16. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008;131:120-131.
17. Politis M, Wu K, Loane C et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010;40:216-221.
18. Strecker K, Wegner F, Hesse S, et al. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. J Neurol 2011;258:19-26.
19. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-1833.
20. Muñoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008;131:3380-3394.
21. Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest 2014;124:1340-1349.
22. 11C]DASB PET study in Parkinson's disease. Neuroimage 2012;59:1080-1084.
23. Stachowiak MK, Bruno JP, Snyder AM, Stricker EM, Zigmond MJ. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res 1984;291:164-167.